RBC Capital analyst Douglas Miehm raised the firm’s price target on Bausch Health (BHC) to $10 from $8.50 and keeps a Sector Perform rating on the shares ahead of the company’s Q3 report due after market close on October 30 following Bausch + Lomb’s (BLCO) Q3 results due before market open on the same day. The firm estimates Q3 revenue of $2.39B versus the FactSet consensus of $2.42B and adjusted EBITDA of $832M versus the FactSet consensus of $839M, noting that it expects the focus to be on the strategic priority relating to B+L following multiple unconfirmed news articles over the last month indicating that the company is working with advisers to test interest from potential buyers. The firm now includes a B+L sale scenario with 75% probability, driving its increased price target for Bausch Health shares.
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See the top stocks recommended by analysts >>
Read More on BHC:
- Bausch Health call volume above normal and directionally bullish
- Bausch Health turns down bondholders’ debt proposals, WSJ reports
- Galecto announces the appointment of Wechsler to its Board of Directors
- M&A News: TPG and Blackstone Could Eye Joint Bid for Bausch + Lomb (NYSE:BLCO)
- TPG, Blackstone teaming for Bausch + Lomb bid, may be up to $25/share, FT says
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
